The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).
 
David J. Sermer
No Relationships to Disclose
 
Santosha Adipudi Vardhana
Honoraria - Agios
Consulting or Advisory Role - ADC Therapeutics; Immunai
 
Ashley Ames
No Relationships to Disclose
 
Erin Biggar
No Relationships to Disclose
 
Alison J. Moskowitz
Honoraria - ADC Therapeutics; Kiowa Kirin; miRagen; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Incyte; Merck; Seagen
 
Connie Lee Batlevi
Honoraria - Dava Oncology
Consulting or Advisory Role - Celgene; Gerson Lehrman Group; Juno Therapeutics; Kite, a Gilead company; Lifesci Capital; Lifesci Capital; Seagen
Research Funding - Bayer (Inst); Epizyme; Janssen Biotech; Novartis; Xynomic Pharma
 
Philip Caron
No Relationships to Disclose
 
Audrey M. Hamilton
No Relationships to Disclose
 
Craig H. Moskowitz
Consulting or Advisory Role - Merck
 
Matthew J. Matasar
Stock and Other Ownership Interests - Merck
Honoraria - Bayer; Genentech; GlaxoSmithKline; Janssen; Pharmacyclics; Roche; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Teva
Research Funding - Bayer; Genentech; GlaxoSmithKline; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen
 
Andrew David Zelenetz
Stock and Other Ownership Interests - Adaptive Biotechnologies
Honoraria - Clinical Care Options; NCCN; Oncology Information Group; PER
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Cancer Support Community; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; Karyopharm Therapeutics; Medscape; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Prime Education; TRM Oncology; Vaniam Group; Verastem
Research Funding - BeiGene; Genentech/Roche; Gilead Sciences; MEI Pharma
 
Steven M. Horwitz
Consulting or Advisory Role - ADC Therapeutics; Affimed Therapeutics; Astex Pharmaceuticals; Celgene; Corvus Pharmaceuticals; Innate Pharma; Kura Oncology; Kyowa Hakko Kirin; Millennium; miRagen; Portola Pharmaceuticals; Seagen; Takeda; Verastem
Research Funding - ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Forty Seven (Inst); Kyowa Hakko Kirin (Inst); Seagen (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Verastem (Inst)
 
Gottfried Von Keudell
No Relationships to Disclose
 
Joachim Yahalom
No Relationships to Disclose
 
Jurgen Rademaker
No Relationships to Disclose
 
Ahmet Dogan
Consulting or Advisory Role - Abbvie; EUSA Pharma; Roche; Seagen; Takeda
Research Funding - Roche/Genentech
 
Venkatraman E. Seshan
No Relationships to Disclose
 
Anas Younes
Honoraria - Abbvie; Curis; Epizyme; Janssen; Merck; Roche; Takeda
Consulting or Advisory Role - Bio-Path Holdings, Inc; Celgene; Epizyme; HCM; Roche; Xynomic Pharma
Research Funding - Bristol-Myers Squibb (Inst); Curis (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); Roche (Inst); Syndax (Inst)